Publications by authors named "D J DeAngelo"

Claim this Profile
V
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML.
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, Anna Bosch-Vilaseca, Kevin M Panaro, Daniel J DeAngelo

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.
Luis E Aguirre, Richard M Stone, Daniel J DeAngelo, Maximilian Stahl

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials.
Andrew Hantel, Yating Wang, Angel Cronin, Irum Khan, Ivy Elizabeth Abraham, Daniel J DeAngelo

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.
H Moses Murdock, Haesook T Kim, Katie Maurer, Amar H Kelkar, Roman M Shapiro, Daniel J DeAngelo

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.
Emma-Jayne Minihane, Leah Krotee, Jason Wu, Lindsey Thornton, Geoffrey Fell, Daniel J DeAngelo

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis